Loan agreement with subsidiary of the Company

Date: 30th October, 2026 Corporate Filings Department, Listing Compliance Department, BSE Limited, National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai- 400 001. Mumbai - 400 051. Security Code: 532815 Symbol: SMSPHARMA Dear Sir/Madam, Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 This is further to our letter dated July 31, 2026, and in compliance with Regulation 30 read with Schedule III of Listing Regulations, we hereby inform you that the Company has entered into a Loan Agreement with SMS Peptides Private Limited, a subsidiary of the Company. The details as required in terms of Regulation 30 and Schedule III of the SEBI Listing Regulations, read with SEBI Circular SEBI/HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 are enclosed as Annexure -A. Please take the above intimation on your records. Thanking you Yours faithfully For SMS Pharmaceuticals Limited Thirumalesh Tumma Company Secretary & Compliance Officer Annexure -A Sr. No. Particulars Details 1. Name(s) of parties with whom the Loan Agreement has been entered between agreement is entered SMS Pharmaceuticals Limited (Company/ SMS Pharma/Lender) and SMS Peptides Private Limited (SMS Peptides/Borrower), a Subsidiary of the Company 2. Purpose of entering into the The Company has entered a loan agreement agreement with SMS Peptides Private Limited a Subsidiary of the Company to provide loan to subsidiary company for its business purpose. 3. Size of agreement Up to an aggregate amount not exceeding Rs. 50 Crores, in one or more trenches. 4. Shareholding, if any, in the entity with The Company is holding 99.99% stake in the whom the agreement is executed SMS Peptides as on date. 5. Significant terms of the agreement (in No such special rights brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc 6. Whether, the said parties are related Yes, SMS peptides is the Subsidiary of SMS to promoter/promoter group/ group pharma having common Directors companies in any manner. If yes, nature of relationship 7. Whether the transaction would fall Yes, the transaction is at arm’s length basis. within related party transactions? If yes, whether the same is done at “arm’s length” 8. In case of issuance of shares to the Not Applicable parties, details of issue price, class of shares issued 9. In case of loan agreements, details of Lender: SMS Pharmaceuticals Limited lender/borrower, nature of the loan, Borrower: M/s. SMS Peptides Private Limited total amount of loan granted/taken, Nature of loan: Unsecured loan total amount outstanding, date of Amount of loan: Up to an aggregate amount execution of the loan not exceeding Rs. 50 Crores (Rupees Fifty Crore agreement/sanction letter, details of Only) the security provided to the lenders / Date of execution of Loan Agreement: 30th by the borrowers for such loan or in October, 2026 case outstanding loans lent to a party Amount of loan outstanding as on date of or borrowed from a party become disclosure – Nil material on a cumulative basis 10. Any other disclosures related to such NIL agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc 11. In case of termination or amendment Not Applicable of agreement, listed entity shall disclose additional details to the stock exchange(s): i. name of parties to the agreement; ii. nature of the agreement; iii. date of execution of the agreement; iv. details of amendment and impact thereof or reasons of termination and impact thereof